InnoCan Pharma (TSE:INNO)

:INNO

INNO

InnoCan Pharma

RESEARCH TOOLSreports

Want to see TSE:INNO full AI Analyst Report?

InnoCan Pharma (INNO) Price & Analysis

23 Followers

INNO Stock Chart & Stats

C$7.50

C$0.01(5.26%)

At close: Jan 08 4:00 PM EST

C$7.50

C$0.01(5.26%)

Day’s Range― - ―

52-Week RangeC$5.00 - C$21.00

Previous CloseN/A

Volume118.77K

Average Volume (3M)920.00

Market Cap

C$22.49M

Enterprise ValueC$10.60M

Total Cash (Recent Filing)C$6.69M

Total Debt (Recent Filing)C$930.00K

Price to Earnings (P/E)2.7

Beta-0.44

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.24

Shares Outstanding4,498,772

10 Day Avg. Volume392

30 Day Avg. Volume920

Financial Highlights & Ratios

PEG Ratio0.48

Price to Book (P/B)3.90

Price to Sales (P/S)0.82

P/FCF Ratio45.60

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong EquityA conservatively levered balance sheet with low debt and positive equity provides durable financial flexibility. Over 2-6 months this lowers refinancing risk, supports continued R&D and clinical programs, and gives the firm capacity to fund development without urgent external financing.

Positive Operating And Free Cash Flow (2025)Transitioning to positive operating and free cash flow is a structural improvement in liquidity and runway. If sustained it reduces dilution risk, funds near-term development milestones and commercialization activities, and improves the company's ability to execute without immediate capital raises.

Proprietary Drug-delivery FocusOwning proprietary delivery technology in the cannabinoid therapeutics niche creates durable competitive advantages: IP, differentiation in formulation and controlled-release, and potential for licensing or higher product margins across veterinary and human markets.

Bears Say

Continued Net LossesOngoing net losses mean the business still relies on existing cash or new capital to fund operations and R&D. Over months this constrains strategic optionality, can force financing at unfavorable terms, and limits ability to deliver shareholder returns until profitability is sustained.

Cooling Revenue TrendA deceleration from prior rapid scaling and recent revenue decline weakens the business case for operating leverage. If top-line growth is cooling, the company may struggle to absorb fixed costs, slow progress toward break-even, and face tougher commercialization economics.

Inconsistent Historical Cash Flow & Small ScalePrior multi-year cash burn and a very small operating footprint increase execution risk. Limited internal resources and inconsistent cash generation make sustaining trials, scaling manufacturing, or commercialization harder without external support, raising structural operational risk.

InnoCan Pharma News

Innocan Pharma Secures Additional Insider Debenture Ahead of Planned U.S. Offering

The latest announcement is out from InnoCan Pharma ( ($TSE:INNO) ). Innocan Pharma has closed an additional US$200,000...

2M ago

Innocan Pharma Secures Additional Insider Debenture Financing Ahead of Planned U.S. Offering

InnoCan Pharma ( ($TSE:INNO) ) has provided an update. Innocan Pharma plans to issue an additional US$200,000 debenture...

2M ago

Innocan Pharma Secures Insider Debenture Financing Ahead of Planned U.S. Listing

InnoCan Pharma ( ($TSE:INNO) ) has issued an update. Innocan Pharma plans to issue a US$450,000 secured debenture...

2M ago

Innocan’s Long-Acting CBD Injection Shows Superiority to Placebo in Canine Pain Trial

InnoCan Pharma ( ($TSE:INNO) ) has issued an announcement. Innocan Pharma reported that its liposomal synthetic cannabidiol (LPT-CBD)...

3M ago

Innocan Pharma Targets NYSE American Listing With Concurrent Offering

The latest announcement is out from InnoCan Pharma ( ($TSE:INNO) ). Innocan Pharma Corporation plans to list its...

4M ago

Innocan Pharma Targets NYSE American Listing with Concurrent Securities Offering

InnoCan Pharma ( ($TSE:INNO) ) has shared an update. Innocan Pharma Corporation plans to list its common shares...

5M ago

Innocan Pharma Unveils Promising Advances in CBD Drug Delivery Platform

InnoCan Pharma ( ($TSE:INNO) ) has provided an announcement. Innocan Pharma announced promising preliminary findings regarding its liposomal...

5M ago

Innocan Pharma Files Amended Registration for U.S. Public Offering

InnoCan Pharma ( ($TSE:INNO) ) has provided an announcement. Innocan Pharma has announced the public filing of an...

5M ago

Innocan Pharma Reports 2025 Financial Results

Innocan Pharma Corporation ( ($INNPF) ) has released its Q3 earnings. Here is a breakdown of the information...

6M ago

Innocan Pharma Reports Q3 2025 Results and Advances Drug Delivery Platform

InnoCan Pharma ( ($TSE:INNO) ) just unveiled an announcement. Innocan Pharma reported its Q3 2025 financial results, showing...

6M ago

INNO FAQ

What was InnoCan Pharma’s price range in the past 12 months?

InnoCan Pharma lowest stock price was C$5.00 and its highest was C$21.00 in the past 12 months.

What is InnoCan Pharma’s market cap?

InnoCan Pharma’s market cap is C$22.49M.

When is InnoCan Pharma’s upcoming earnings report date?

InnoCan Pharma’s upcoming earnings report date is Jun 01, 2026 which is in 11 days.

How were InnoCan Pharma’s earnings last quarter?

InnoCan Pharma released its earnings results on Mar 30, 2026. The company reported C$0.618 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.618.

Is InnoCan Pharma overvalued?

According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does InnoCan Pharma pay dividends?

InnoCan Pharma does not currently pay dividends.

What is InnoCan Pharma’s EPS estimate?

InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does InnoCan Pharma have?

InnoCan Pharma has 4,498,772 shares outstanding.

What happened to InnoCan Pharma’s price movement after its last earnings report?

InnoCan Pharma reported an EPS of C$0.618 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.062%.

Which hedge fund is a major shareholder of InnoCan Pharma?

Currently, no hedge funds are holding shares in TSE:INNO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

InnoCan Pharma

InnoCan Pharma (INNO) is a biotechnology company focused on developing innovative therapeutic solutions leveraging cannabinoid-based technologies. The company operates primarily in the pharmaceutical and wellness sectors, with a core emphasis on creating advanced treatments for various medical conditions, including dermatological ailments and neurological disorders. InnoCan Pharma is known for its proprietary delivery systems that enhance the bioavailability of cannabinoids, aiming to revolutionize how these compounds are utilized in medical applications.